Sirnaomics: Funding, Investors & Team (Oct 2026)
Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAhead™ mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics based on Sirnaomics proprietary GalAhead™ mxRNA technology, targeting ApoC3 mRNA for cardiovascular disease treatment. STP237G is the first dual-targeted drug based on a GalAhead™ muRNA technology and is in the late stage of preclinical evaluation. The Group has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the expansion of the Group's clinical pipeline and establishment of the Group's manufacturing facility, Sirnaomics focuses on a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.
Sirnaomics has raised $114M across 3 funding rounds on record, the most recent an undisclosed round of $7.6M announced in Oct 2024.
That round is in line with the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sirnaomics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Sirnaomics Funding Rounds
Sirnaomics raised $105M in an undisclosed round announced in Oct 2020.
2.6 years later, an undisclosed round of $1.0M was announced in May 2023.
1.4 years later, an undisclosed round of $7.6M was announced in Oct 2024.
Sirnaomics Founders and Leadership Team
Contact details for the Sirnaomics team: 1 of 3 have an email address on file.
Start 14-day free trial →Sirnaomics Funding Compared to Other Biotechnology Startups
Sirnaomics' latest round of $7.6M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sirnaomics in Biotechnology and Gaithersburg
Companies Similar to Sirnaomics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Sirnaomics Funding FAQs
What does Sirnaomics do?
Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAhead™ mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics based on Sirnaomics proprietary GalAhead™ mxRNA technology, targeting ApoC3 mRNA for cardiovascular disease treatment. STP237G is the first dual-targeted drug based on a GalAhead™ muRNA technology and is in the late stage of preclinical evaluation. The Group has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the expansion of the Group's clinical pipeline and establishment of the Group's manufacturing facility, Sirnaomics focuses on a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.
How much funding has Sirnaomics raised?
Sirnaomics has raised $114M across 3 rounds on record. The most recent is an undisclosed round of $7.6M announced in Oct 2024.
When did Sirnaomics last raise funding?
Sirnaomics' most recent funding round on record is an undisclosed round of $7.6M, announced in Oct 2024.
Who founded Sirnaomics?
FundedIQ lists David Evans (Founder), George Ji (Founder) at Sirnaomics.
Who is the CEO of Sirnaomics?
Patrick Lu is listed as CEO at Sirnaomics.
Where is Sirnaomics headquartered?
Sirnaomics is based in Gaithersburg, Maryland, United States.
How many employees does Sirnaomics have?
Sirnaomics is in the 101-250 employee band.
How does Sirnaomics' funding compare to other Biotechnology startups?
Sirnaomics' latest round of $7.6M is in line with the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Sirnaomics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sirnaomics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.